YAP1 and cholangiocarcinoma: Subsequent studies have demonstrated that the concurrent activation of YAP and AKT in hepatocytes leads to the development of cholangiocellular carcinoma (CCA) [11, 13], a tumor that is frequently observed in patients with primary sclerosing cholangitis (PSC) (Fig. 1A).